µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º $~2Ao[
9#agI|d~
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ <ImeZ'L7
>s>5k
O
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) qlzL<
E^qKkl
1. ICAM-1 6yR7RF}
VP"L_Um
2. interleukin 12(IL-12) ;xRy
ONt
?LW1D+
3. tumor infiltrating lymphocyte \ pq]q
fGxa~Unx
4. TCR/CD3 complex b
:+
X3
=]"PSY7p
5. hematopoietin receptor family L2:C6Sc
9:m+mpL=9
6. individual idiotype(IdI) |_A35"v
-}>Q0d )
7. integrin 4f>Vg$4
,JjTz
O
8. colony-stimulatory factor (CSF) y
K{~
D4S>Pkv
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© ;TR.UUT
+[>m`XTq
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? 5zUD W?
18`?t_8g
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ *AJW8tIP
4A*'0!H
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷ÓᣠNc7YMxk'H
Aw5yvQ>]e
4. ¼òÊö¿¹ÔÌá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ h qxe
ptsi\ 7BG
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) m*(8I=]q
Vdjca:`
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔÀí¡£ rSa3u
*xB
BO1Mz=q
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) {!<zk+h$
~UL;O\-b0
3. immunoglobulin superfamily (IgSF) =XqmFr;h
x&kF;UC
4. selectin BK-{z).)
U/TF,JUI
5. anti-idiotypic antibody (¦ÁId) |{Oe&j3|
6 s*#y[$
6. major histocompatibility complex(MHC) C7nLa@
g4U%(3,>D
7. immunotolerance |J8c|h<
RU@`+6j+
8. biological reponse modifier(BRM) 1YQ|KJ*K
t.3b\RV[
9. immune reponse gene (Ir gene) $_NVy>\&
-MeGJX:^I
10. reshaped antibody (or reconstituted antibody) HD$W\P
>+&524xc
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© '(~+
\
Lxs
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ oS, %L
4OC^IS
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? L_Ff*
+H8]5~',L%
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ l7n c8K
zcy!Y
B
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? QT&2&#Z
up#W"`"
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ DFcgUEq
X6kCYTJYF
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? j!F5gP-l
Ho2#'lSKM
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ 3)3?/y)_
>
;LXy
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ iP)`yB5 `
j KGfm9|zj
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔÀíºÍ½á¹û²â¶¨? *2P%731n5
3MH9%*w'0
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ !{>'jvH
V:s$V.{!
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: JZ3CC f
@y]ek/
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: #ue
WU
XYj!nx{k,
̉񧄤 _3~/Z{z8
KPHtD4
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© |qm_ESzl
ZRHK?wg'#
1. CD8 fqpbsM;M]
!LJE o>D
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) ,Pi!%an w
S#Q
0aGj
3. immunoglobulin fold(Ig fold) Is&0h|
Rxb?SBa
4. cadherin (Ca-dependent cell adhesion moleculers) SbLm
5ir
Ffr
5. idiotype-anti-idiotypic antibody immune network theory w2X0.2)P2
2i0 .x
6. HLA class II antigen )+7|_7
!x
F+@/ "1c
7. complementarity-determining region (CDR) *Ri\7CqU"6
I%(YR"
8. perforin(or pore-forming protein ,PFP) amTeTo]Tg
j)nL!":O
9. high affinity IL-2 receptor ,ArHS
Nwwn #+
10. artificial active immunization I4XnJ[N%
M}fk[Yr>
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© PfR|\{(
g?.y7!m
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ^%n]_[RUn4
Yj CH KI"e
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 ='vD4}"j
gU&y5s~
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ oyT`AYa
]4ib^R~Z
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ H@xHkqan
dAWB.#
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔÀí¡£ G{.[o6>
jj&mRF0gCb
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? u\{MQB{T
"4IrW6B$9
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ^sKdN-{
8NkyT_\
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ iE EP~
#iKPp0`K*
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ 9^u}~e
#(
/a*8z,x
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ ~GE|,Np
4bCA"QM[[
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© )&DsRA7v
;Fo7 -kK
1. immunoglobulin gene rearrangement Q
'ZZQ
?)ct@,Ek$
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) IgjPy5k
E-%$1=;
3. flow cytometry(FCM) q*Oj5;
Y<IuwS
4. carrier effect \2!.
*8Su:=*b
5. positive selection of T lymphocytes in thymus F Uz1P
T
Xiu/g(
6. mouse TH1(Th1) and TH2(Th2) subsets }3,
4B-8!
k.7!)jL7
7. perforin (pore-forming protein ,PFP) <"K2t
Tg.
_M&n~ r
8. ADCC(antibody-dependent cell-mediated cytotoxicity)
lI%RdA[
BL~#-Mm<|l
9. SH-2(src-homology region 2) _k :BY
ePZAi"k
10. Ab2¦Â (internal image) Y}xM&%
E=8GSl/Jx
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© @{UUB=}9
JhjH_)
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? :{^~&jgL
t*; KxQ+'?
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? QgKR=GR6
BQ<\[H;
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦ÓᣠJU;`c>8=)
]%I\FefT
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ FZ}^)u}o
`mW~ {)x
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠj!kJ@
l bP
:/%Y"0
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) 2@?X>,
tBfmjxv
ÃâÒßѧרҵ£º Z m%,L$F*L
C-)d@LWI
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ M%la@2SK=
Ywv\9KL
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? )A%* l9\nG
TQKcPVlE
´«È¾²¡Ñ§×¨Òµ£º *
U6+b
,?Ie!r$6
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ wkPjMmW+!
CshME\
/
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ ra6\+M~}e
,52Lm=n
Ïû»¯×¨Òµ£º oJ*
,a
gE
$Uv*Gj
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹ÔÑо¿µÄ½øÕ¹¡£ +6l#hO7h
t:V._@
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? vf@j d}?
N>YSXh`W`y
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ J5F@<vi
L fcy#3!
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 3M+rFB}tS
X
EbVsw
1. Fas(CD95)/FasL %XeN_
V
{4A,&pR
2. common chain of cytokine receptor LQr!0p.i"
&y1iLk h ^
3 . TCR/CD3 complex yA"?Hv \o;
`Mt|+iT$p
4. negaive selection of thymocytes P (7Q8i
'
r5UVBV8T
5. artificial active immune %z1^
Q|{b8K
6. anti-idiotypic - E
GZ
m
F~]P8
7. IgSF u
6?9#L(
`?R{sNr.
8. Integrin '" %0UflJS
R_g(6l"3R^
9. chemokine BF2U$-k4
o!~XYEXvUa
10. B7/CD28 R31Z(vY
{V(~
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© +aEm]=3
j7Y7&x"
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԲÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹ÔµÄ¹ý³Ì¡£ k
Qr
s#aj5_G
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ BQ u8$W
4.wrY6+V
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ M[z1B!rT
XI[n!)3
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô»òÖ×ÁöÏà¹Ø¿¹Ô,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ cMT:Ij];
e~(e&4pb
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô¡£ p.8
c-(dm:
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ # }}6JM
s:xJ }Ll
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© tK
e-Dk9
zb4@U=?w}
1. B7/CD28 Wp:vz']V
Da8gOZ
2. Th1 subset ]R}(CaT1
T+B-R\@t
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© ]9w8[T:O
zGz}.-F
4. antibody affinity maturation PknKzrEG:>
%f("3!#H
5. AP-1 ']\SX*z?
fDW:|%{Y,
6. single chain variable fragment£¨ScFv£© k\SqDmv
:5j+^/
7. NK cell receptor n^|xp;] :
)nj fqg
8. Zinkernagel-Doherty phenomenon l"`VvW[
@VIY=qh
9. Ig fold t@MUNW`Q
C%E~9_w
10. CD40/CD40L j<BRaT
y*sVimx
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© i={4rZOD^
D8~\*0->
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ 1c]{rO=taN
DQ/rx`BG
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ J> ,w},`
[ypE[
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ Wvu1?
t$VRNZ`dy
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ gq*W 0S
)OFN0'
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ HRbv%
[hot,\+f
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ OIw[sum2
*5s*-^'#!
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ Fz<1xyc(
1~E4]Ef:W
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© dZ*&3.#D5
bxL'k/Y$
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© .L1[Rv3
bYem0hzOe
1.Co-stimulators (or co-stimulating molecules) OKau3T]
+.^pAz U}R
2.NK-kB ~~"U[G1
ABp8PD
3.Immunoglobulin superfamily rbv
ir\)Hz2P
4.antigen-presenting cell (APC) %1GKN|7
GeB-4img
5.death domain ,SdxIhL
,d.5K*?aI
6.CCR and CXCR {`)oxzR
'ju_l)(R
7.Lectin (or mitogen) +5R8mbD!
fh1-]$z`~
8.Clusters of differentiation, CD) As^eL/m2L
B 2_fCSlg
9.B7 family ]JmE(Y1(1
Q=[ IO,f
10.Cytotoxic T lymphocyte, CTL) r~,3
-<T>paE9
11.IL-15 and IL-15 receptor (IL-15R) &FZ~n?;hQ
,PKUgL}w
12.MHC restriction &i`(y>\
_|MK0'+f
13.Affinity-chromatography M[iWWCX
+zo\#8*0MF
14.Cyctosprin A, CsA Yyw3+3
C4-%|+Q i
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) q!5`9u6
28}L.>5k
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© {Ov{O,c5
(Nf!E[}Z
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 %(\et%[]
R"F: (
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ Vm I
Afe
3Dj>U*fP
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹ÔµÄÌØµã¡£ _4k zlD
00Ye
]j_
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© uS xldc
N{Pa&/V
ÃâÒßѧרҵ£º zrC1/%T
/|v
b)J
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ `w"ooK
N=!k2+
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ `yRt?UQRS
]0}NF
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔÒò£¨Ìõ¼þ£©ÊÇʲô£¿ Qgo|\=
H]{`q
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) k/Ao?R=@gI
uUv^]B 8GM
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) ORIXcj]
G98f Bw
1. ADCC(antibody dependent cell-mediated cytotoxicity) ^/$U(4
07,&weQ
2. »·æß¾úËØ(cyclosporin) T&E'MB
#<-%%
3. KIR(killer cell inhibitory receptor) 0
\o5+
_=I&zUF
4. HLDA(human leucocyte differentiation antigen) [ofZ1hB4
*!}bU`
5. Interleukin 18(IL-18) [XNDYaF8
i%r+/D)KvG
6. ÕûºÏËØ(integrin) 7{OD/*|
)=#zMdK&
7. Fas/FasL -JdNA2P
2)|G%f_lS
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) !<0 `c
A4TW`g_zm
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) .JWN\\
,Y0qGsV
10. Th1/Th2 *XG.?%x*|
7hKfxw-X@
11. »ùÒòÒßÃç(DNAÒßÃç) di~ [Ivw
]P4?
jKI
12. chemokines and chemokine receptor 7$J
E+gL/7
.oe\wJ S6
13. ÃâÒßÄÍÊÜ tAS[T9B
%u*HNo
14. ¹²´Ì¼¤·Ö×Ó sl G%o5|m
UH7FIM7kX
15. ËÀÍö½á¹¹Óò(death domain) 81S0: =
)bB
Va^
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) n wO5<b;
3^Z@fC
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? Ev1gzHd!i
VJ-To}
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠbMN]co
9_J'P2e
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î X;yThb`iI
lxtt+R
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ O|0,=
5
Qa,$_,E
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå 0Q:l,\lY
Q^Q6|
n
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ $&.
rS.*
(6X{ &
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) $%?[f;S3,
ic?(`6N8
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ L
[X"N
88A,ll%
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ opon"{
d(9C7GLC,
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£